Best Practices in Rare Disease Commercialization

Commercializing a rare disease therapy is unlike any other launch. Small patient populations, fragmented specialist networks, and long diagnostic odysseys demand a strategy built specifically for the rare disease context. This white paper lays out the core commercialization principles that separate successful rare disease launches from those that stall.